Secret pharma deals may erode Trump's most-favored-nation drug pricing savings

An analysis suggests that confidential agreements between the Trump administration and pharmaceutical companies could significantly reduce the projected savings from the 'most-favored nation' pricing policy. The extent of these deals and their impact on actual drug prices remains uncertain, but the finding challenges the policy's stated fiscal benefits.